Summary
The claims evaluate a manufacturer savings/copoly program rather than any FDA-approved prescribing information content. The supplied label excerpts provided do not contain information about eligibility, income/FPL thresholds, pharmacy participation, insurance coverage rules, or copay cards; therefore these claims cannot be supported and are treated as unsupported/absent from the provided prescribing information.
Category Scores
Accurate Statements
Unsupported Statements
Vascepa's savings program is available to patients who have a Vascepa prescription filled at a participating pharmacy.
No information about any savings program, participating pharmacies, or eligibility mechanics is present in the supplied prescribing information sections.
Vascepa's savings program eligibility requires that out-of-pocket costs are not covered by a third-party payer.
The supplied prescribing information contains no terms for savings program eligibility related to third-party payer coverage or out-of-pocket cost criteria.
Vascepa's savings program is available to patients with a household income at or below 400% of the federal poverty level (FPL).
No content in the supplied prescribing information specifies income thresholds, FPL, or patient eligibility criteria for any savings program.
For patients with a high deductible health plan (HDHP) or without health insurance, Vascepa's savings program offers savings on out-of-pocket costs.
The supplied prescribing information provides no information about HDHP/uninsured status handling or any savings on out-of-pocket costs.
Patients with commercial insurance may be eligible for Vascepa's savings program if their out-of-pocket costs are not covered by their insurance.
The supplied prescribing information contains no statements about commercial insurance eligibility conditions for a savings program.
Vascepa's savings program offers a copay card to help reduce out-of-pocket costs for Vascepa prescriptions.
No information in the supplied prescribing information references a copay card or cost-reduction program.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
These claims concern reimbursement/cost-assistance program structure rather than the drug’s medical use, safety risks, contraindications, or dosing. However, because they are not supported by the provided prescribing information excerpts, they may mislead about program availability/eligibility.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
All claims are about a patient savings/coplay program and are absent from the provided FDA-approved prescribing information excerpts; therefore they are unsupported against the supplied label content.
Suggested Improvement
Remove these savings-program assertions or replace them with information that is explicitly present in the FDA-approved label content provided. If evaluating cost-assistance, use the official program terms/website rather than the prescribing information excerpts.